Biogen Inc. (BMV:BIIB)

Market Cap	483.91B
Revenue (ttm)	184.63B
Net Income (ttm)	29.50B
Shares Out	n/a
EPS (ttm)	201.30
PE Ratio	16.40
Forward PE	13.86
Dividend	n/a
Ex-Dividend Date	n/a

Volume	36
Average Volume	285
Open	3,321.30
Previous Close	3,344.00
Day's Range	3,290.00 - 3,321.30
52-Week Range	2,395.00 - 3,356.00
Beta	0.15
RSI	67.55
Earnings Date	Feb 12, 2026

About Biogen

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar r...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1978
• Employees: 7,605
• Stock Exchange: Mexican Stock Exchange
• Ticker Symbol: BIIB

Financial Performance

In 2024, Biogen's revenue was $9.68 billion, a decrease of -1.62% compared to the previous year's $9.84 billion. Earnings were $1.63 billion, an increase of 40.57%.

Financial numbers in USD